PT  - JOURNAL ARTICLE
AU  - Barbra, Mutamba
AU  - Alice, Nyamwiza
AU  - Kassa, Dawit
AU  - Rulisa, Stephen
TI  - Assessment of Accuracy and Reliability: Validation trial for a Fluorescent Probe-Based Real-Time PCR Assay Kit in Detecting Human Papillomavirus Nucleic Acid
AID  - 10.1101/2024.10.29.24316338
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.10.29.24316338
4099  - http://medrxiv.org/content/early/2024/11/01/2024.10.29.24316338.short
4100  - http://medrxiv.org/content/early/2024/11/01/2024.10.29.24316338.full
AB  - Background Human Papillomavirus (HPV) infection is a potential risk for cervical cancer, the latter is the fourth leading cause of cancer related death worldwide. Effective testing procedures are particularly important in its prevention and management. More accurate HPV tests replace traditional cytology based screening, and they are in line with national and international guidelines that recommend primary HPV testing due to its better efficacy. The purpose of the study was to confirm that these Gynius HPV detection kits were equal in efficiency compared with Roche Cobas HPV assay based testing, which could better facilitate earlier detection and stratification by risk level for cervical lesions. Methods The prospective parallel control study recruited 1000 women from the district hospitals of Kibagabaga and Muhima in Rwanda. Participants were tested for HPV DNA tests using both Roche and Gynius kits and then the samples were sent to Rwanda National Reference Laboratory. We analyzed the concordance of two Gynius variants (liquid and lyophilized ) and Roche across for several different HPV subtypes, such as 16, 18 or other high risk types (31,33,35,39,45,51,52,56,58,59,66,68,73,53,82 &26). Statistics like sensitivity, specificity, predictive values and consistency (Kappa) were calculated to compare the concordance of assays. Results We found that the Gynius HPV solution is exceptionally easy to implement in laboratory settings within low and middle income countries (LMICs). It offers effective sampling control through color detection, making it highly suitable for self sampling procedures. Additionally, the Gynius HPV solution includes an automated extraction system that completes full plate extraction in under 20 minutes. The Gynius solution is compatible with various qPCR systems, eliminating the need for costly qPCR machine repurchases. Using lyophilized reagents, which can be stored and transported at room temperature, it bypasses the need for a cold chain and refrigeration. The Gynius solution also has a high sample processing capacity. For instance, using the BioRad CFX96, it can produce up to 1,200 results per day per machine; with the BioRad CFX384, it can generate up to 4,000 results per day making it ideal for large scale screening. In a comparison of 987 samples, high risk HPV detection rates were consistent across all three tests: Roche (20%), Gynius liquid (23%), and Gynius lyophilized (21%). Concordance analysis showed high agreement rates, with both Gynius kits achieving over 80% compatibility with Roche for detecting HPV 16, 18, and other virus subtypes. Conclusion This study provides compelling evidence for the efficacy of the Gynius HPV kits (both lyophilized and liquid formulations), which demonstrated high concordance rates with established assays for detecting high risk HPV genotypes, particularly HPV 16 and 18. Engineered specifically for low and middle income countries (LMICs), the Gynius HPV kits integrate innovative sampling and detection technologies optimized for resource limited settings, facilitating seamless implementation. These findings indicate that Gynius HPV kits present a viable and scalable solution for cervical cancer screening programs, with the potential to significantly enhance early detection capabilities and broaden preventive care accessibility.Competing Interest StatementThe authors have declared no competing interest.Funding Statementwe got funding from gynius to test the new kitsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study adhered to ethical standards, and before proceeding obtained approval from the Rwanda National Ethics Committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yesdata is available when requested